Introduction
Kheiron Medical Technologies is a London-based medical imaging company founded in 2016 that develops deep learning software to support radiologists in breast cancer screening. Peter Kecskemethy co-founded Kheiron and served as Chief Executive Officer — a role confirmed in acquisition communications and industry materials reviewed alongside Kheiron’s corporate site in July 2026. Kheiron’s flagship product Mia (Mammography Intelligent Assessment) supports screening programs as an independent reader, concurrent reader, and triage tool.
In 2024 Kheiron became part of DeepHealth, a global AI-powered health informatics company and wholly owned subsidiary of RadNet, Inc. — a consolidation that extends Mia’s reach through DeepHealth’s SmartMammo breast screening portfolio while preserving Kheiron’s London headquarters heritage referenced on kheironmed.com.
What the company does
Kheiron develops Mia, AI software that analyzes mammograms to assist radiologists in detecting breast cancers earlier and managing screening workload. Mia received CE marking in Europe in 2019 and was deployed in the UK’s first prospective evaluation of breast screening AI — results Kheiron published showing twelve percent more cancers detected with potential thirty percent workload savings in that evaluation context per the company’s official news article path cited in this profile.
Following DeepHealth acquisition, Mia capabilities integrate into SmartMammo — DeepHealth’s cloud-native breast cancer diagnosis solution supporting high-volume screening programs including RadNet’s Enhanced Breast Cancer Detection initiative in the United States. Kecskemethy stated in acquisition communications that joining DeepHealth would equip more radiologists globally with tools to detect subtle lesions and optimize screening.
Mia’s independent-reader regulatory pathway differentiated Kheiron from triage-only AI vendors — a distinction national screening programs weigh heavily when evaluating AI augmentation policies.
Who it serves
Kheiron serves national breast screening services, hospital radiology departments, and imaging networks — particularly in the United Kingdom and European markets where CE-marked Mia deployed before U.S. expansion through DeepHealth/RadNet channels. Screening program directors evaluate Mia for cancer detection sensitivity and reader workload reduction; radiologists interact with Mia inside established screening workflows rather than standalone AI viewers.
Hospital Services Limited partnership brought Mia to health services in Northern Ireland and the Republic of Ireland — geographic expansion referenced in Kheiron news materials prior to DeepHealth integration.
Company background
Kecskemethy founded Kheiron in 2016 in London with a vision to apply deep learning and data science to breast screening — a domain where radiologist supply constraints and rising cancer incidence create pressure for AI augmentation. Kheiron won the UK AI in Health and Care Award in 2020 and gained visibility including New York Times coverage of patient impact referenced in Kecskemethy speaker biographies. The 2024 DeepHealth acquisition by RadNet placed Kheiron within a U.S.-listed imaging network actively consolidating AI vendors including prior acquisitions of Quantib and Aidence.
Kecskemethy’s computer science and Oxford postdoctoral background in high-performance computing informed Kheiron’s technical approach — serial entrepreneurship experience prior to Kheiron included multiple tech startups before focusing on cancer diagnostics.
Product and AI capabilities
Mia applies deep learning to mammography images trained on diverse screening populations, validated through prospective evaluation rather than retrospective accuracy claims alone. Independent-reader CE clearance enables Mia to contribute to screening decisions within regulated frameworks — a higher bar than computer-aided detection tools limited to triage prioritization.
DeepHealth integration aims to combine Mia’s clinical validation with SmartMammo operational infrastructure — buyers should monitor product branding and support transitions post-acquisition when contracting screening AI across UK and U.S. markets.
Key developments
2016: Kheiron founded in London. 2019: Mia CE marking in Europe. 2020: AI in Health and Care Award. 2024: Kheiron became part of DeepHealth/RadNet (kheironmed.com timeline). UK prospective evaluation results published at cited kheironmed.com news URL.
Why it matters
Kheiron matters because breast screening AI adoption hinges on prospective clinical evidence and regulatory clearance type — Mia’s independent-reader pathway and UK evaluation results address both. DeepHealth acquisition shows imaging network operators acquiring AI screening assets rather than relying solely on vendor partnerships — a consolidation pattern Brel readers tracking medical imaging AI should monitor alongside companies like Lunit. Kecskemethy’s founding story exemplifies European screening AI leadership later absorbed into U.S. imaging network scale.
Sector context
Kheiron belongs in Brel’s AI in healthcare coverage under medical imaging and breast screening AI, related to mammography vendors and distinct from digital pathology platforms. Readers should verify current commercial branding under DeepHealth SmartMammo when evaluating contracts — acquisition integration may change support and product roadmaps.
Sources and references
Kheiron UK prospective evaluation news article and Our team page.
- Kheiron — UK prospective breast screening AI evaluation (kheironmed.com)
- Kheiron — Our team (kheironmed.com)
Reviewed July 10, 2026. Peter Kecskemethy is Co-Founder and CEO. bbc.co.uk removed per batch 3 rules.